ArticleNature communications2023
In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy response in lung cancer.
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 31 papers.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
9.1field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 38 citations in OpenAlex.
- Cancer-Intrinsic Protein Neddylation Modulates the Intratumoral Immune Landscape to Constrain Immune Checkpoint Blockade Therapy.Cancer immunology research · 2026Article
- Advancing targeted protein degradation: pLIRTAC's role in glioma and CAR-T cell therapy.Autophagy · 2026Article
- CAF-derived PAI-1 serves as an EGFR ligand and fuels KRAS-mutant pancreatic cancer.Nature communications · 2026Article
- SerpinB7 promotes c-Myc-mediated glycolysis by interacting with ANXA2 to facilitate the progression of non-small cell lung cancer.Molecular cancer · 2026Article
- Mesenchymal stromal cells counteract with age-related immune decline and enhance vaccine efficacy by modulating endogenous splenic marginal reticular cells in elderly models.Cellular & molecular immunology · 2026Article
- EML4-ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis.Cancer discovery · 2026Article
- High-throughput screening to engineer optimal T cell therapies: current knowledge and future prospects.Frontiers in oncology · 2026Review
- Cancer Genomic Alterations and Microenvironmental Features Encode Synergistic Interactions with Disease Outcomes.Molecular cancer research : MCR · 2025Article
- Genomic copy-number variants drive apoptotic evasion underlying acquired resistance to immune checkpoint inhibitors.Immunity · 2025Article
- STAT1 promotes ferroptosis and inflammation in mouse hepatic ischemia-reperfusion injury.Communications biology · 2025Article
- Methods and applications of in vivo CRISPR screening.Nature reviews. Genetics · 2025Review
- Targeting spermine metabolism to overcome immunotherapy resistance in pancreatic cancer.Nature communications · 2025Article
- Cellular Landscape of Synovial Chondromatosis Synovium Revealed by Single-Cell RNA Sequencing.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- Perturbomics: CRISPR-Cas screening-based functional genomics approach for drug target discovery.Experimental & molecular medicine · 2025Review
- Catalytic-state structure of Candidatus Hydrogenedentes Cas12b revealed by cryo-EM studies.Nucleic acids research · 2025Article
- Immuno-oncology recapitulates ontogeny: Modern cell and gene therapy for cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Rational development of gemcitabine-based nanoplatform for targeting SERPINB9/Granzyme B axis to overcome chemo-immune-resistance.Nature communications · 2025Article
- Functional and molecular single-cell analyses implicate PRDM14 in the initiation of B cell leukemia in mice.Scientific reports · 2025Article
- Finding a needle in a haystack: functional screening for novel targets in cancer immunology and immunotherapies.Oncogene · 2025Review
- High-throughput screening for optimizing adoptive T cell therapies.Experimental hematology & oncology · 2024Review
Corrections and comments
- Erratum issued
Authors and funding
25 authors at 6 institutions in 2 countries.
Dzana DervovicCentre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.
Ahmad A MalikCentre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-6254-0403
Edward L Y ChenCentre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.
Masahiro NarimatsuCentre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.
Nina AdlerComputational Biology Program, Ontario Institute for Cancer Research, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-0297-2706
Somaieh Afiuni-ZadehCentre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.
Dagmar KrenbekDepartment of Pathology and Bacteriology, Klinik Floridsdorf, Vienna, Austria.
Sebastien MartinezCentre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.
Ricky TsaiCentre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.ORCID http://orcid.org/0000-0001-5916-6978
Jonathan BoucherInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, QC, Canada.
Jacob M BermanCentre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.
Katie TengCentre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.
Arshad AyyazCentre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.
YiQing LüCentre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.ORCID http://orcid.org/0000-0001-5896-031X
Geraldine MbamaluCentre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.
Sampath K LoganathanCentre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-8809-1466
Jongbok LeeToronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada.
Li ZhangToronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada.
Cynthia GuidosSickKids Research Institute, University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-7674-2612
Jeffrey WranaCentre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.ORCID http://orcid.org/0000-0003-0932-0644
Arschang ValipourKarl-Landsteiner-Institute for Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria.
Philippe P RouxInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, QC, Canada.ORCID http://orcid.org/0000-0002-5962-0250
Jüri ReimandDepartment of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Hartland W JacksonCentre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.ORCID http://orcid.org/0000-0001-6423-2415
Daniel SchramekCentre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada. schramek@lunenfeld.ca.ORCID http://orcid.org/0000-0001-9977-2104
Mount Sinai Hospital · CAUniversity Health Network · CAInstitute for Research in Immunology and Cancer · CAOntario Institute for Cancer Research · CAKarl Landsteiner Society · ATUniversity of Toronto · CA
Funding
CIHR 419699CIHR 438792
Abstract
How the genetic landscape governs a tumor's response to immunotherapy remains poorly understood. To assess the immune-modulatory capabilities of 573 genes associated with altered cytotoxicity in human cancers, here we perform CRISPR/Cas9 screens directly in mouse lung cancer models. We recover the known immune evasion factors Stat1 and Serpinb9 and identify the cancer testis antigen Adam2 as an immune modulator, whose expression is induced by Kras
Indexed as
Antineoplastic AgentsFertilinsLung NeoplasmsSerpinsAnimalsAntigens, NeoplasmHumansImmunotherapyMaleMembrane ProteinsMiceT-Lymphocytes, CytotoxicTumor MicroenvironmentADAM2 protein, humanAdam2 protein, mouseAntigens, NeoplasmAntineoplastic AgentsFertilinsMembrane ProteinsSERPINB9 protein, humanSerpinb9 protein, mouseSerpins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.